Walleye Trading
BCRX icon

Walleye Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Walleye Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,300
Closed -$25.7K – 4141
2025
Q4 		$25.7K Buy
+3,300
New +$23.9K ﹤0.01% 4079
2024
Q1 		– Sell
-27,800
Closed -$167K – 4760
2023
Q4 		$167K Sell
27,800
-19,500
-41% -$113K ﹤0.01% 3889
2023
Q3 		$335K Buy
47,300
+35,000
+285% +$251K ﹤0.01% 3279
2023
Q2 		$86.6K Sell
12,300
-4,300
-26% -$34.5K ﹤0.01% 3806
2023
Q1 		$138K Sell
16,600
-85,600
-84% -$824K ﹤0.01% 3718
2022
Q4 		$1.17M Buy
102,200
+13,600
+15% +$170K ﹤0.01% 2102
2022
Q3 		$1.12M Buy
88,600
+87,000
+5,438% +$1.12M ﹤0.01% 2168
2022
Q2 		$17K Sell
1,600
-1,800
-53% -$18.6K ﹤0.01% 4547
2022
Q1 		$55K Sell
3,400
-109,500
-97% -$1.76M ﹤0.01% 4478
2021
Q4 		$1.56M Sell
112,900
-186,200
-62% -$2.46M 0.01% 1844
2021
Q3 		$4.3M Buy
299,100
+44,500
+17% +$702K 0.02% 1023
2021
Q2 		$4.03M Buy
+254,600
New +$3.46M 0.02% 930
2021
Q1 		– Sell
-7,200
Closed -$54K – 4804
2020
Q4 		$54K Buy
+7,200
New +$37.1K ﹤0.01% 4158

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Walleye Trading's BCRX Position: Q1 2026 in Review

Walleye Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 23,777 shares — an estimated $185K sold.

Walleye Trading first reported a position in BCRX in Q2 2015 and held it in 19 quarters. The position peaked at $1.79M in Q3 2021. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Walleye Trading reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 23,777 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $185K.
  • Walleye Trading first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 19 quarters.
  • Walleye Trading's BioCryst Pharmaceuticals position peaked at $1.79M in Q3 2021.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.